ATE552344T1 - Viren mit erhöhter lytischer kraft - Google Patents

Viren mit erhöhter lytischer kraft

Info

Publication number
ATE552344T1
ATE552344T1 AT03729255T AT03729255T ATE552344T1 AT E552344 T1 ATE552344 T1 AT E552344T1 AT 03729255 T AT03729255 T AT 03729255T AT 03729255 T AT03729255 T AT 03729255T AT E552344 T1 ATE552344 T1 AT E552344T1
Authority
AT
Austria
Prior art keywords
viruses
target cells
increased lytic
functional
cells
Prior art date
Application number
AT03729255T
Other languages
English (en)
Inventor
Beusechem Victor Van
Willem-Ronald Gerritsen
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Application granted granted Critical
Publication of ATE552344T1 publication Critical patent/ATE552344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03729255T 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft ATE552344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075108A EP1327688A1 (de) 2002-01-14 2002-01-14 Adenoviren mit erhöhter Lysisfähigkeit
PCT/EP2003/000340 WO2003057892A2 (en) 2002-01-14 2003-01-14 Viruses with enhanced lytic potency

Publications (1)

Publication Number Publication Date
ATE552344T1 true ATE552344T1 (de) 2012-04-15

Family

ID=8185521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729255T ATE552344T1 (de) 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft

Country Status (6)

Country Link
US (1) US8052965B2 (de)
EP (2) EP1327688A1 (de)
AT (1) ATE552344T1 (de)
AU (1) AU2003235764A1 (de)
ES (1) ES2385347T3 (de)
WO (1) WO2003057892A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258060B2 (en) * 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
EP1586654A1 (de) * 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
AU2006262021C1 (en) 2005-06-23 2012-05-10 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN103122360A (zh) * 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
EP2043662B1 (de) * 2006-07-26 2015-09-09 Intrexon Corporation Verfahren und zusammensetzungen zur behandlung von krankheiten
WO2011133040A2 (en) 2010-04-23 2011-10-27 Orca Therapeutics B.V. Replication-competent adenoviruses
WO2012047109A2 (en) 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CA2914790C (en) 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
CN105524161A (zh) * 2016-02-05 2016-04-27 南通大学 抗肿瘤小分子多肽piddδ及其载体和应用
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
WO2020046130A1 (en) 2018-08-31 2020-03-05 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
DE69725882T2 (de) * 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
WO2000029573A2 (en) * 1998-11-18 2000-05-25 Canji, Inc. Adenoviral vectors
ATE540686T1 (de) * 1999-05-12 2012-01-15 Uab Research Foundation Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
CA2379171A1 (en) * 1999-07-15 2001-01-25 Introgen Therapeutics, Inc. Methods for treatment of hyperproliferative diseases using human mda-7
JP2003516743A (ja) * 1999-12-14 2003-05-20 ジェノボ， インコーポレイテッド 複製不能アデノウイルスの製造のための方法および組成物
AU3976900A (en) * 2000-04-04 2001-10-15 Christopher Barry Wood Combination of p53 gene and e1b-deleted p53 gene
WO2002088327A1 (en) * 2001-04-06 2002-11-07 Mount Sinai School Of Medicine Of New York University Methods for viral oncoapoptosis in cancer therapy

Also Published As

Publication number Publication date
EP1327688A1 (de) 2003-07-16
AU2003235764A8 (en) 2003-07-24
WO2003057892A2 (en) 2003-07-17
AU2003235764A1 (en) 2003-07-24
EP1466001A2 (de) 2004-10-13
EP1466001B8 (de) 2012-11-21
WO2003057892B1 (en) 2004-05-13
US8052965B2 (en) 2011-11-08
EP1466001B1 (de) 2012-04-04
WO2003057892A3 (en) 2004-02-26
US20050220765A1 (en) 2005-10-06
ES2385347T3 (es) 2012-07-23

Similar Documents

Publication Publication Date Title
ATE552344T1 (de) Viren mit erhöhter lytischer kraft
DE69417734D1 (de) Cytopathische viren zur therapie und prophylaxe der neoplasie
NO20024157D0 (no) Kasein-avledete peptider og anvendelser derav i terapi
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
BR0214650A (pt) Imunocitoquinas com seletividade modulada
DK0462187T3 (da) Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer
ATE500808T1 (de) Onkolytische virustherapie
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
DK0958371T3 (da) Cytopatiske vira til behandling og forebyggelse af neoplasi
UA85379C2 (ru) Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы
ATE346859T1 (de) Zusammensetzung zum zellspezifischen transfer von wirkstoffen
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
CA2449013A1 (en) Viral mutants that selectively replicate in targeted human cancer cells
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
WO2006038129A3 (en) Hepatitis c virus replication system
DK285986D0 (da) Proteiner af typen human che samt fremgangsmaade til fremstilling heraf
WO2000066743A3 (en) Viral expression vectors
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.
AR033582A1 (es) Sistema de muerte celular en plantas
WO2003016474A3 (en) Methods and compositions for use in selectively producing a protein in telomerase expressing cells
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
FI963755A0 (fi) Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaavat yhdistelmä-DNA-tekniset virukset